Michael S. Weiss
Tracked across 1 events · 6 articles · First seen Jan 13, 2026 · Last active Mar 09, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Michael S. Weiss, CEO and Chairman of TG Therapeutics, expressed satisfaction with the company's 2025 performance and optimism for 2026, highlighting Ublituximab's success and ongoing clinical advancements.
Jan 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Michael S. Weiss live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard